Expert Review of Pharmacoeconomics & Outcomes Research最新文献_第3页

Cost-utility analysis of latanoprost unidose cationic emulsion preservative-free versus latanoprost unidose in the treatment of open-angle glaucoma and ocular hypertension patients in Spain. 西班牙无防腐剂拉坦诺前列素与无防腐剂拉坦诺前列素阳离子乳剂治疗开角型青光眼和高眼压的成本-效用分析。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-09-08 DOI: 10.1080/14737167.2025.2556693

María Isabel Canut, Julián García-Feijoo, Jose Manuel Larrosa-Poves, Fernando López-López, Marta Pazos, Nataly Espinoza-Cámac, Itziar Oyagüez, Teresa Del Rio, Maria Rodríguez

{"title":"Cost-utility analysis of latanoprost unidose cationic emulsion preservative-free versus latanoprost unidose in the treatment of open-angle glaucoma and ocular hypertension patients in Spain.","authors":"María Isabel Canut, Julián García-Feijoo, Jose Manuel Larrosa-Poves, Fernando López-López, Marta Pazos, Nataly Espinoza-Cámac, Itziar Oyagüez, Teresa Del Rio, Maria Rodríguez","doi":"10.1080/14737167.2025.2556693","DOIUrl":"10.1080/14737167.2025.2556693","url":null,"abstract":"Background: This study evaluated the efficiency CE-latanoprost unidose (cationic emulsion of latanoprost) versus latanoprost unidose (non-emulsion formulation) in open-angle glaucoma and ocular hypertension (OAG/OHT) with concomitant ocular surface disease (OSD) patients' treatment in Spain.Methods: A cost-utility analysis was performed using a Markov model simulating the progression of OAG/OHT. From a Spanish National Health System perspective over a 5-year time horizon, quality-adjusted life years (QALYs) and the total cost of each therapy were estimated (annual discount rate: 3%). Therapy efficacy included adherence, disease progression, and OSD reduction. Utility values for OAG/OHT and OSD-related disutility values were obtained from literature. Five ophthalmologists validated all included parameters. Total costs (€, 2023) included CE-latanoprost or latanoprost drug acquisition (€10/30 single-dose), glaucoma diagnosis, patient follow-up, and OAG management costs.Results: The base case results showed that CE-latanoprost unidose increased health outcomes (2.69 vs. 2.49 QALYs) and lowered costs (€5,292.12 vs. €5,441.55) being a dominant option (0.21 QALYs gained and €149.43 less) compared to latanoprost unidose.Conclusions: CE-latanoprost unidose was a cost-effective option for the treatment of patients with OAG/OHT and OSD in comparison to latanoprost unidose (non-emulsion formulation). In addition to its clinical benefits, the economic analysis supports using CE-latanoprost in terms of efficiency.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-7"},"PeriodicalIF":1.5,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A comprehensive measurement of hemophilia economic burden in Iraq: a field-based study. 伊拉克血友病经济负担的综合衡量：一项实地研究。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-09-08 DOI: 10.1080/14737167.2025.2558090

Baraa Ghani Abdulraheem, Ali Azeez Al-Jumaili, Safa Mohammed Shaukat Mohammed Khalid

{"title":"A comprehensive measurement of hemophilia economic burden in Iraq: a field-based study.","authors":"Baraa Ghani Abdulraheem, Ali Azeez Al-Jumaili, Safa Mohammed Shaukat Mohammed Khalid","doi":"10.1080/14737167.2025.2558090","DOIUrl":"10.1080/14737167.2025.2558090","url":null,"abstract":"Background: This study assessed the economic burden of hemophilia A, B, and A with inhibitors, including direct medical, non-medical, and indirect costs from both governmental and patient perspectives.Research design and methods: A retrospective cost-of-illness analysis was conducted at a public hospital in Baghdad, Iraq serving hemophilia patients. Government costs were derived from medical records, while patient out-of-pocket expenses were gathered via interviews. Data were collected from November 2024 to March 2025. One-way ANOVA tested cost differences across hemophilia types and severity levels.Results: The Ministry of Health spent US$11.30 million annually on 446 hemophilia patients (average $25,312 per patient), with clotting-factor replacement comprising 70.6% of the costs. On-demand treatment accounted for 84.5% of the hospitalization expenses. Patients with hemophilia-A-with-inhibitors incurred the highest annual cost ($113,651), followed by hemophilia-B and hemophilia-A-without-inhibitors cases. Severe cases and comorbidities like hepatitis C further increased spending. Non-medical costs averaged $440.33, and indirect costs $281.42 per patient. School absenteeism totaled 1,753 days across 144 students, averaging 12.2 days each.Conclusion: Clotting-factor replacement remains the primary cost driver in hemophilia care, with inhibitors significantly increasing expenditures. Non-medical and indirect costs add to the overall burden, underscoring the need for prophylaxis and access to innovative therapies.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-12"},"PeriodicalIF":1.5,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145000011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The potential public health impact of new immunization strategies for the prevention of RSV in children in Panama. 预防巴拿马儿童呼吸道合胞病毒的新免疫策略的潜在公共卫生影响

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-09-01 Epub Date: 2025-06-04 DOI: 10.1080/14737167.2025.2514530

Xavier Sáez-Llorens, Pieralessandro Lasalvia, Paola Jaramillo, Rodrigo DeAntonio

{"title":"The potential public health impact of new immunization strategies for the prevention of RSV in children in Panama.","authors":"Xavier Sáez-Llorens, Pieralessandro Lasalvia, Paola Jaramillo, Rodrigo DeAntonio","doi":"10.1080/14737167.2025.2514530","DOIUrl":"10.1080/14737167.2025.2514530","url":null,"abstract":"Objective: New prophylaxis to reduce the burden of respiratory syncytial virus (RSV) disease are available, including a long-acting monoclonal antibody (nirsevimab) and maternal immunization with an RSV prefusion F protein vaccine (RSVpreF). We compared the potential public health impact of these strategies when implemented in Panama from the payer perspective.Methods: A static model evaluated the use of year-round nirsevimab with/without catch-up, seasonal nirsevimab with catch-up, and RSVpreF in a birth cohort. Health, cost, quality-of-life outcomes, and the number needed to immunize (NNI) were compared to the current standard of care, followed by an indirect comparison of nirsevimab and RSVpreF.Results: Seasonal nirsevimab with catch-up would be the most effective strategy as it would prevent 62% RSV-associated lower respiratory tract disease cases compared to RSVpreF, followed by year-round nirsevimab with catch-up that would prevent 46% of cases. Each of the nirsevimab strategies would have a greater impact on all outcomes compared to RSVpreF. The NNI to prevent an RSV infection and death was lower for the nirsevimab strategies compared to RSVpreF.Conclusion: RSV immunization strategies would significantly reduce the disease burden in Panama. Nirsevimab would have a greater public health impact than RSVpreF due to its sustained efficacy and protection regardless of gestational age.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1073-1086"},"PeriodicalIF":1.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144208076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Collaborative economic tools for prevention strategies: case of the EQUIPT model. 预防战略的协作经济工具：EQUIPT模式的案例。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-09-01 Epub Date: 2025-07-05 DOI: 10.1080/14737167.2025.2529363

Kei Long Cheung, Mickaël Hiligsmann

引用次数: 0

Incorporating diagnostic testing into economic evaluations of tumour-agnostic therapies. 将诊断测试纳入肿瘤不可知论治疗的经济评估。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-09-01 Epub Date: 2025-07-09 DOI: 10.1080/14737167.2025.2532023

Tamás Zelei, Gábor Kovács, Shirin Ashrafganjouei, Tamás Ágh

{"title":"Incorporating diagnostic testing into economic evaluations of tumour-agnostic therapies.","authors":"Tamás Zelei, Gábor Kovács, Shirin Ashrafganjouei, Tamás Ágh","doi":"10.1080/14737167.2025.2532023","DOIUrl":"10.1080/14737167.2025.2532023","url":null,"abstract":"Introduction: Tumor-agnostic treatments represent paradigm shift in oncology, targeting specific genetic mutations irrespective of the tumor's anatomical origin. This personalized approach relies on companion diagnostic testing to identify patients likely to respond to treatment. However, incorporating molecular diagnostics poses challenges to healthcare systems, particularly regarding costs and accessibility. This must be addressed in economic evaluations to guide health technology assessment and reimbursement decisions.Areas covered: This study reviewed economic evaluations of tumor-agnostic therapies, focusing on the role of diagnostic testing. A literature search identified 13 compounds targeting nine molecular alterations, with eight relevant publications analyzed. The review revealed heterogeneity in how diagnostic testing is incorporated into cost-effectiveness models. While some studies excluded the costs and consequences of diagnostic tests entirely, others included them partially or fully. Key findings underscore the substantial impact of testing, particularly for low-prevalence biomarkers.Expert opinion: Integrating diagnostic testing into economic evaluations is essential for accurately assessing the health economic value of tumor-agnostic therapies. Economic models must account for test-treatment combinations and consider shifts in treatment pathways compared to routine practice. As the field evolves, the development of robust frameworks and clear guidance on the requirements are crucial to support sustainable and equitable healthcare decision-making.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1005-1010"},"PeriodicalIF":1.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Economic and developmental impacts of FDA designations: a systematic review and meta-analysis. FDA指定的经济和发展影响：系统回顾和荟萃分析。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-09-01 Epub Date: 2025-05-21 DOI: 10.1080/14737167.2025.2507426

Joab Williamson, Syed Shahzad Hasan, Vijay S Gc

{"title":"Economic and developmental impacts of FDA designations: a systematic review and meta-analysis.","authors":"Joab Williamson, Syed Shahzad Hasan, Vijay S Gc","doi":"10.1080/14737167.2025.2507426","DOIUrl":"10.1080/14737167.2025.2507426","url":null,"abstract":"Introduction: U.S. FDA designations: Breakthrough Therapy (BTD), Fast Track (FTD), Orphan Drug (ODD), and Regenerative Medicine Advanced Therapy (RMAT) aim to expedite drug development, yet their combined economic and developmental effects have not been extensively studied. This systematic review evaluates their impacts on Day 1 cumulative average abnormal returns (CAAR) and timelines from Investigational New Drug submission to approval.Methods: A systematic search of PubMed, Scopus, ScienceDirect, GreyNet, OpenGrey, ProQuest, and Cochrane Library was conducted for articles published between January 1997 and September 2024. A random-effects model generated pooled estimates with 95% confidence intervals (CI), and heterogeneity was assessed using the Cochrane-Q and I2 statistic. Study quality was evaluated using Drummond's checklist and an adapted Barker checklist.Results: Twenty-five studies were included. The pooled Day 1 CAAR across designations was 6.12% (95% CI: 3.64-8.61). Subgroup analysis revealed FTD with the strongest immediate market impact (8.20%%, 95% CI: 4.38-12.03) and BTD with the shortest mean approval timeline (69.96 months, 95% CI: 60.25-79.67).Conclusions: FDA designations provide economic advantages, especially for smaller companies, and can expedite approvals for high-priority therapies. Notable heterogeneity, particularly with RMAT, warrants further research to clarify how disease area and company size shape real-world outcomes.Registration: ResearchRegistry ID11080.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1051-1061"},"PeriodicalIF":1.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adherence to asthma and COPD inhaled therapies in low- and middle-income countries: a narrative review. 低收入和中等收入国家对哮喘和慢性阻塞性肺病治疗的依从性：一项叙述性回顾

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-09-01 Epub Date: 2025-06-17 DOI: 10.1080/14737167.2025.2520898

Vaibhav Gaur, Alessandra Sorano, Himanshu Sankrityayan, Jaideep Gogtay, Federico Lavorini

{"title":"Adherence to asthma and COPD inhaled therapies in low- and middle-income countries: a narrative review.","authors":"Vaibhav Gaur, Alessandra Sorano, Himanshu Sankrityayan, Jaideep Gogtay, Federico Lavorini","doi":"10.1080/14737167.2025.2520898","DOIUrl":"10.1080/14737167.2025.2520898","url":null,"abstract":"Introduction: In low-income and middle-income countries (LIMCs), defined based on the World Bank classification, non-adherence to respiratory therapies contributes to increasing mortality and morbidity due to chronic respiratory diseases. To address this issue, it is essential to identify and tackle underlying factors such as cultural beliefs, socioeconomic disparities, and limited access to healthcare resources and infrastructures. The absence of strategies that integrate community involvement, healthcare professional's training, economic policies, and educational programs exacerbates the disproportionate burden of chronic respiratory diseases in LIMCs.Areas covered: This review is based on a structured literature search across PubMed, Scopus, and Google Scholar (2000-2023) using terms relevant to asthma, COPD, adherence, and LMICs. The review examines key factors that hinder patients' adherence to Asthma and COPD medications in LIMCs, providing some insights into the issue and proposing concrete solutions.Expert opinion: Addressing non-adherence requires a multifaceted approach involving community engagement, educational initiatives, and improved healthcare infrastructure. Future research should focus on tailored interventions to enhance adherence and ultimately improve health outcomes for patients with chronic respiratory diseases in LMICs.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"993-1003"},"PeriodicalIF":1.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development and implementation of a stratified enhanced recovery after surgery pathway for ventral hernia repair. 腹疝修补手术后分层增强恢复路径的发展和实施。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-09-01 Epub Date: 2025-06-18 DOI: 10.1080/14737167.2025.2520409

James Espeleta, Sunitha Singh, Ethan Augustine, Artem Shmelev, Zhaosheng Jin, Daryn Moller

{"title":"Development and implementation of a stratified enhanced recovery after surgery pathway for ventral hernia repair.","authors":"James Espeleta, Sunitha Singh, Ethan Augustine, Artem Shmelev, Zhaosheng Jin, Daryn Moller","doi":"10.1080/14737167.2025.2520409","DOIUrl":"10.1080/14737167.2025.2520409","url":null,"abstract":"Introduction: Enhanced recovery after surgery (ERAS) pathways are widely adopted in both major and minimally invasive surgeries. However, ERAS pathway implementation in ventral hernia repair (VHR) surgery remains an area of ongoing research given the variability in hernia complexity and surgical approach. To address this, our institution proposed and developed a stratified ERAS pathway to deliver effective, tailored perioperative care.Areas covered: This narrative describes the development of the ERAS pathway stratified to address the varied perioperative needs of VHR procedures, outline the evidence-based interventions comprising the bundle, describe the implementation process, and discuss the potential economic impact of implementing this pathway. We conducted a systematic literature search, last updated on 15 February 2024.Expert commentary: By leveraging the common elements of ventral hernia repair ERAS pathways, while addressing the perioperative needs of patients undergoing more complex procedures, a stratified pathway approach provides a practical and adaptable framework that balances intervention specificity with ease of implementation. While the introduction of conditional element modifications increases pathway complexity, it also facilitates patient-centered delivery of care. Operational expertise in organizing such pathways, as well as the implementation science behind it, is an opportunity to advance the frontiers of ERAS program developments.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"981-992"},"PeriodicalIF":1.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144283152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Methodological approaches in the economic evaluation of prognostic and predictive companion diagnostics: a systematic scoping review. 在预测和预测伴随诊断的经济评价的方法学方法：系统范围审查。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-09-01 Epub Date: 2025-06-22 DOI: 10.1080/14737167.2025.2519744

Tuukka Hakkarainen, Haavisto Ira, Leskelä Riikka-Leena

{"title":"Methodological approaches in the economic evaluation of prognostic and predictive companion diagnostics: a systematic scoping review.","authors":"Tuukka Hakkarainen, Haavisto Ira, Leskelä Riikka-Leena","doi":"10.1080/14737167.2025.2519744","DOIUrl":"10.1080/14737167.2025.2519744","url":null,"abstract":"Introduction: This systematic scoping review aimed to identify and analyze current methodological approaches used in model-based economic evaluations (EEs) of prognostic and predictive companion diagnostics (pCDx), highlighting methodological gaps and challenges.Methods: Systematic searches were conducted in PubMed and Scopus (January 2009-March 2023). Included studies were model-based EEs, methodological papers, or reviews specifically addressing prognostic or predictive CDx. Data extraction followed the modified CHEERS checklist. Results were synthesized narratively across six methodological domains. No formal risk of bias assessment was done per scoping review conventions.Results: Eighty-eight studies were included, of which 60 were model-based EEs. Most studies utilized Markov cohort models (37%) or decision tree-Markov hybrids (30%). Quality-adjusted life-years (QALYs) were the main outcome (88%). Only 15% of studies derived clinical utility from randomized controlled trials, and fewer than half explicitly modeled diagnostic accuracy. Methodological limitations included inconsistent modeling of real-world test-treatment pathways, insufficient consideration of pretest probabilities, diagnostic thresholds, and inadequate uncertainty analyses.Conclusions: This review identified variability and methodological gaps in economic evaluations of pCDx. Standardizing evaluation methods, integrating real-world evidence, and systematically considering the diagnostic accuracy and uncertainty could improve the robustness of pCDx evaluations. Limitations of this study included overrepresentation of breast cancer studies.Registration: OSF Registries (22 February 2023) DOI 10.17605/OSF.IO/GVFMQ.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1037-1049"},"PeriodicalIF":1.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Healthcare resource utilization and associated costs in patients with metastatic castration-resistant prostate cancer in Greece. 希腊转移性去势抵抗性前列腺癌患者的医疗资源利用及相关费用

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-09-01 Epub Date: 2025-05-23 DOI: 10.1080/14737167.2025.2505726

E Bournakis, A Bournakis, D V Zolota, E Kostouros, F Zagouri, A P Papatheodoridi, A Andrikopoulou, M Tsiatas, K Karalis, R Zakopoulou, A Mamali, C Christodoulou, I Binas, A Ardavanis, D Mauri, G Emmanouil, I Dimitriadis, A Bamias

{"title":"Healthcare resource utilization and associated costs in patients with metastatic castration-resistant prostate cancer in Greece.","authors":"E Bournakis, A Bournakis, D V Zolota, E Kostouros, F Zagouri, A P Papatheodoridi, A Andrikopoulou, M Tsiatas, K Karalis, R Zakopoulou, A Mamali, C Christodoulou, I Binas, A Ardavanis, D Mauri, G Emmanouil, I Dimitriadis, A Bamias","doi":"10.1080/14737167.2025.2505726","DOIUrl":"10.1080/14737167.2025.2505726","url":null,"abstract":"Background: Prostate cancer is a leading cause of cancer death among men. Metastatic castration-resistant prostate cancer (mCRPC) treatment has changed dramatically since the introduction of novel hormonal agents (NHAs); however, real-world data including healthcare resource utilization (HCRU) and costs are lacking in Greece.Methods: A subset of patients with HCRU data from the PROSPECT retrospective chart review study of patients with mCRPC who initiated first line (1 L) systemic therapy with chemotherapy or NHAs were included; HCRU and costs incurred during mCRPC treatment were estimated.Results: HCRU remained mostly stable across lines for the 119 patients included. Overall, median HCRU cost was €2,363.8 per patient per month (PPPM); 1 L was €2,475.0, second line (2 L) was €1,698.9, third line (3 L) was €2,499.0. Cost was mostly made up of systemic treatment (~90%). Overall HCRU 2 L costs were €688,795.1, contributing the least to the total HCRU cost of the three lines studied (€3,820,561.1). 2 L cost was lower as a greater proportion of patients received chemotherapy than in 1 L or 3 L, and chemotherapy was cheaper than NHAs.Conclusions: Cost was impacted by type of systemic treatment; 2 L treatment costs were lower as a higher proportion of patients were treated with chemotherapy rather than NHAs.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1063-1072"},"PeriodicalIF":1.5,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144126971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0